[MESO-1,2-BIS(2,6-DICHLORO-4-HYDROXYPHENYL)ETHYLENEDIAMINE]-DICHLOROPLATINUM(II), A NEW DRUG NOT ONLY PARENTERALLY BUT ALSO ORALLY-ACTIVE IN THE THERAPY OF BREAST AND PROSTATE-CANCER

SPRUSS, T and SCHERTL, S and SCHNEIDER, MR and GUST, R and BAUER, K and SCHONENBERGER, H (1993) [MESO-1,2-BIS(2,6-DICHLORO-4-HYDROXYPHENYL)ETHYLENEDIAMINE]-DICHLOROPLATINUM(II), A NEW DRUG NOT ONLY PARENTERALLY BUT ALSO ORALLY-ACTIVE IN THE THERAPY OF BREAST AND PROSTATE-CANCER. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 119 (12). pp. 707-716. ISSN 0171-5216,

Full text not available from this repository.

Abstract

The platinum complex [meso-1,2-bis(2,6-dichloro-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II), K, was tested for its antitumor activity on hormone-sensitive tumor models under peroral administration. The resorption from the gastrointestinal tract was proved by determining the estrogenic effect of K in a dose/activity study using the immature-mouse uterine weight test. In comparison to the subcutaneous injection, a tenfold peroral dose was administered to achieve identical effects. By peroral treatment of the hormone-sensitive MXT(M3.2) mammary carcinoma of the mouse with K an almost complete inhibition of the tumor growth was obtained. This effect was superior to that of subcutaneously applied cisplatin and significantly better than that obtained by perorally administered ligand L at an equimolar dose, indicating that the antitumor effect is caused by the intact complex K and not by the liberated ligand L. The strong antitumor activity of perorally applied K was also demonstrated on the hormone-sensitive Noble Nb-R prostatic carcinoma of the rat. Histological examinations showed that the platinum complex K did not cause cisplatin-like kidney damage or irritations of gastric or intestinal mucosa when given perorally.

Item Type: Article
Uncontrolled Keywords: TUMOR INHIBITING PROPERTIES; MAMMARY-CARCINOMA; PLATINUM COMPLEX; ANTI-ESTROGENS; DIETHYLSTILBESTROL; DNA; DIPHOSPHATE; CISPLATIN; CELLS; RAT; PLATINUM COMPLEX; PERORAL ADMINISTRATION; ESTROGENIC ACTIVITY; ANTITUMOR ACTIVITY; MXT(M3.2) MOUSE MAMMARY TUMOR; NOBLE NB-R RAT PROSTATIC TUMOR; TOXICITY
Depositing User: Dr. Gernot Deinzer
Last Modified: 19 Oct 2022 08:42
URI: https://pred.uni-regensburg.de/id/eprint/53744

Actions (login required)

View Item View Item